Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
141.46
+2.53 (1.82%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Company Description

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits.

In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths.

Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands.

The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.

Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands.

The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Corporation
Repligen logo
Country United States
Founded 1981
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 1,778
CEO Olivier Loeillot

Contact Details

Address:
Building 1, Suite 100
Waltham, Massachusetts 02453
United States
Phone 781 250 0111
Website repligen.com

Stock Details

Ticker Symbol RGEN
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000730272
CUSIP Number 759916109
ISIN Number US7599161095
Employer ID 04-2729386
SIC Code 2836

Key Executives

Name Position
Olivier Loeillot President, Chief Executive Officer and Director
Anthony J. Hunt Executive Chair
Jason K. Garland Chief Financial Officer and Chief Compliance Officer
James R. Bylund Chief Operating Officer
Ralf Kuriyel Senior Vice President of Research and Development
Keith Lee Robinson Chief Information Officer
Sondra S. Newman Global Head of Investor Relations
Neil Whitfield Senior Vice President of Sales
Teresa Ferragamo Senior Director of Marketing
Leslie Galvin Vice President of Human Resources

Latest SEC Filings

Date Type Title
Apr 4, 2025 ARS Filing
Apr 4, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 4, 2025 DEF 14A Other definitive proxy statements
Mar 17, 2025 PRE 14A Other preliminary proxy statements
Mar 17, 2025 144 Filing
Mar 14, 2025 10-K Annual Report
Mar 3, 2025 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Feb 20, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 13, 2025 SCHEDULE 13G/A Filing